Ischemic Heart Disease Flashcards
Vasospastic angina is caused by
Functional changes in epicardial arteries
Stable angina is
Obstructive coronary artery disease
CCS is due to
Structural or functional changes in epicardial or cardiac arteries
Treatment method for CCS is
Use of antiischemic agents and prevention of adverse cardiovascular events
Antiischemic is same as
Antianginal
NO donors are
Glyceril trinitrate and isosorbide mononitrate
1st gen BAB
Propranalol
Non dihydropiridine calcium channel blockers
Verapamil and diltiazem
SA node inhibitor
Ivabradine
Late sodium flow inhibitors
Ranolazine
Hypolipidemic agents are
Atorvastatin, fenofibrate,ezetimibs, evolozumab
Cause of angina
Disrupted balance between oxygen supply and oxygen consumption in myocardium
To restore balance
Reduce oxygen consumption or increase oxygen supply
Decrease in blood supply can be caused by
Increase HR, increase ventricular wall tension, decrease in vessel caliber, decrease in perfusion pressure
Increased oxygen demand can be caused by
Increase in HR, ventricular wall tension,heart contractility, increase in preload and afterload
Antiischemic activity is ensured by
Reduction of preload , afterload and CMV (all these reduce oxygen demand)
Increase Oxygen supply can be provided by
Coronary blood vessel dilation and negative chronotropy (HR)-increase in diastolic filling time)
Nitrates and CCB (dihydropiridine) can also cause
Reflex tachycardia like doxazosin
NO provides peripheral arterial dilation in
High doses,in low doses only venodilation
NO dilates veins , peripheral arteries and coronary artery so it has
Antianginal and hypotensive effect
NO increases
cGMP-causes dephosphorylation of myosin light chain-dilation
Fast and short acting organic nitrate
Glyceril trinitrate (action onset in 1-3 minutes, duration of action 20 to 30 min)
Use of glyceril trinitrate
Angina attack
Long acting isosorbide mononitrate (6-8hr duration of action) use
Prevention of angina attack
Nitrates free interval needed
10 to 12 hr
SE of glyceril trinitrate
Headache , hypotension, reflex tachycardia
Dihydropiridine blockers action
Dilates peripheral arteries and coronary arteries -antianginal and hypotensive effect
Use of dihydropiridine blockers
Prevention of angina attack, prevention of vasospastic angina attack, arterial hypertension
SE of dihydropiridine blockers
Headache, facial flushing, fatigue, peripheral edema ankles, constipation
Non dihydropiridine blockers are
Non vasoselective and has cardiodepressent effect
Non dihydropiridine blockers
Reduce CMV,dilates peripheral and coronary artery,prolongs diastole,reduce AV conduction (antiarrhythmic)
Use of Non dihydropiridine calcium channel blockers
Prevention of angina attack and vasospastic angina attack
CCB suppress
L type voltage dependent calcium channel
L type channel have
Slow or prolonged action but activates quickly, slowly inactive
NO and PGI2 inhibits
Platelet activation
CCB are metabolic poisons because
It increases heart dependence on carbohydrate metabolism than usual fat metabolism+inhibition of insulin release -difficult to use carbohydrates during shock
Life threatening bradyarrythmia is caused in interaction between
Beta blockers and verapamil,on parentaral administration can also cause asystole
Macrolide antibiotics and grapefruit juice can increase the amount of
Calcium antagonist by inhibing CYP 450 enzyme CYP 3A4
Dihydropiridine+ACE inhibitors and/or ARB combined overdose cause
Hypotension
Calcium antagonist intoxication cause
Bradycardia and hypotension
Dihydropiridine cause —-shock
Vasodilatory shock
Verapamil and diltiazem cause —- shock
Combined vasodilatory and cardiogenic shock
Verapamil and diltiazem can also cause
Sinus bradycardia,2nd and 3rd degree AV block, sinus arrest
Verapamil affect
PR interval even in Therapeutic dose
Verapamil
Prolongs PR interval
CCB intoxication non cardiacanifedtations are
Hyperglycaemia, nausea, vomiting, metabolic disorders
Hyperglycaemia is due to
Inhibition of insulin release by CCB
Atropine can be used
Bradyarrythmia
Antidote for CCB toxicity
Calcium chloride or calcium gluconate(improves depression of cardiac contractility)/High dose insulin euglycemic therapy/cardiogenic shock -Epinephrine, Dobutamine, isoproterenol/vasodilatory shock -Norpinephrine and phenylephrine
BAB action
Reduce CMV,Prolon diastole,Reduce AV conduction
Use of BAB
Prevention of angina attack, antihypertensive
SE of BAB
Bradycardia,AV block, Bronchospasm, cold extremities
Nitrate action
Increase HR and contractility and decrease Arterial pressure,EDV, ejection time
BAB and calcium channel blockers action
Increase ejection time and EDV, decrease HR, contractility,arterial pressure
If NO combined with calcium channel blockers or BAB cause
Decrease in HR and Arterial pressure.No change in others
Ivabradine acts on —–channel and Inhibits —-
HCN,Na ion flow in 4th phase of AP in SA node
Ivabradine only cause decrease in
HR,not change contractility or induce vasoconstriction
Use of ivabradin
Prevention of stable angina attack
BAB is used only when
There is BAB intolerance or contraindications,as well as in combination
SE of ivabradin
Light phenomenon in the retina (photopsy), pronounced bradycardia
Ischemia induces accumulation of
Na and calcium ions in myocardium
Ranolazine
Blocks na channel, indirectly reduce intracellular calcium ions,so decrease myocardial tension-decresed oxygen consumption and improve perfusion
Ranolazine reduces the use of
GTN
Atorvastatin action
Inhibition of HMG co A reductase+pleiotropic effects, decrease synthesis of mevalonic acid in liver, Increase LDL receptor and decrease LDL in plasma
Atorvastatin uses
Dyslipidemia and prevention of cardiovascular events
SE of atorvastatin
Hepatic function impairment (hepatopathy), myopathy
Fenofibrate are
Fibric acid derivatives or PPAR alpha agonist
Activation of PPAR alpha leads to activation of
Serum lipoprotein lipase -lipolysis-decrease TG and increase LDL receptor
PPAR receptor are seen in
Blood vessel endothelium
Cholesterol absorption inhibitor is
Ezetimibe
Ezetimibe reduce the
Absorption of cholesterol in enterocyte villi by blocking NPC1L1 transport protein,It doesn’t affect fat soluble vitamins,bile acids,TG
Evolozumab
PCSK9 inhibitor,inhibits LDL receptor degrading enzymes
Evolozumab use —-to bond to PCSK9
Human IgG2 monoclonal antibody
INOCA (vasospastic angina treatment
Calcium channel blockers,long acting organic nitrates
Treatment for microvascular angina with structural changes
BAB,ACE inhibitors,Statins
Treatment for microvascular angina vasospastic (functional form)
CCB,Long acting organic nitrates